Galgani, Ilaria
Annaratone, Margherita
Casula, Daniela
Di Maro, Gennaro
Janssens, Michel
Tasciotti, Annaelisa
Schwarz, Tino
Ferguson, Murdo
Arora, Ashwani Kumar
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Received: 12 October 2021
Accepted: 10 April 2022
First Online: 4 May 2022
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The protocols and associated documents were reviewed and approved by the ethics committee of each participating centre (in Canada, IRB services [SSU00044837, SSU00044747]; in Germany, Ethikkommission der Ärztekammer Nordrhein and Ethik-Kommission der Medizinischen Fakultät der Julius-Maximilians-Universität Würzburg Institut für Pharmakologie und Toxikologie; in UK, East of England—Cambridgeshire and Hertfordshire Research Ethics Committee [17/EE/0450]). All participants provided written informed consent before study entry.
: Not applicable.
: IG, MA, DC, GDM, MJ, AT, and AKA are employed by the GSK group of companies. IG holds shares in the GSK group of companies. DC declares two pending patents (unpublished) and AKA declares a published patent application ‘Methods of Boosting the Immune Response’. TS has received honoraria for lecturing from the GSK group of companies, Pfizer, Bavarian Nordic, Janssen-Cilag, AstraZeneca and Sanofi and personal fees during the conduct of this study from the GSK group of companies, Pfizer, Biogen, Merck Serono, Biotest, Sequirus, Bavarian Nordic, and Sanofi. MF is employed by the Colchester Research Group which received payment from the GSK group of companies for the conduct of this study. The wife of MF is the owner of the Colchester Research Group. IG, MA, DC, GDM, MJ, AT, AKA, TS and MF declare no other financial and non-financial relationships and activities.